all report title image
  • Published On : Sep 2022
  • Code : CMI5255
  • Industry : Pharmaceutical
  • Pages : 156
  • Formats :
Ingographics Image

Skin fibrosis generally occurs in patients who suffer from eosinophilia-myalgia syndrome, scleromyxedema (papular mucinosis) and scleredema. Fibrosis frequently develops as a result of continuous chemical exposure or trauma that causes epidermal or dermal harm. It is characterized by an increase of fibrous connective tissues in the dermis or subcutis and frequently goes hand in hand with persistent inflammation. Fibrosis frequently develops as a result of epidermal or dermal damage brought on by repeated chemical exposure or trauma. An increase in fibrous connective tissues in the dermis is one of its defining features. Systemic sclerosis (SSc also known as scleroderma), which also causes fibrosis in a number of other organs, is characterized by the primary symptom of skin fibrosis. Although, this fibrosis cannot be reversed, it can be treated to some extent using currently available drugs. Dermal fibrosis, which results from a pathologic reaction to wound healing, is excessive skin scarring. Scleroderma, nephrogenic fibrosing dermopathy, mixed connective tissue disease, scleromyxedema, scleredema, and eosinophilic fasciitis are only a few of the many fibrotic skin illnesses that exist.

Market Dynamics

The rise in recent advances in treatment for the skin fibrosis is expected to drive the global skin fibrosis treatment market growth over the forecast period. For instance, in December 2017, according to the data published by the Springer Nature, the new treatment strategy has shown promising results in the treatment of skin fibrosis. The treatment involves the molecular targeting therapy with monoclonal antibody. The positive clinical outcomes had been reported in rituximab (an anti-CD20 antibody) and the tocilizumab (an anti-interleukin-6 (IL-6) receptor antibody).

Key features of the study:

  • This report provides an in-depth analysis of the global skin fibrosis treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global skin fibrosis treatment market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Pharmaxis, Jubilant Cadista, Horizon Pharma USA, Pfizer, Sanofi, F. Hoffmann-La Roche, Boehringer Ingelheim, , Bristol-Myers Squibb Company
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global skin fibrosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global skin fibrosis treatment market

Detailed Segmentation:

  • Global Skin Fibrosis Treatment Market, By Drug Type:
    • Corticosteroids
    • Antifibrotic Drugs
    • Immunotherapy Drugs
    • Other (Immunosuppressant)
  • Global Skin Fibrosis Treatment Market, By Route of Administration:
    • Oral
    • Parenteral
    • Others ( Topical)
  • Global Skin Fibrosis Treatment Market, By Application:
    • Localized forms of scleroderma
    • Eosinophilic fasciitis
    • Scleromyxedema (papular mucinosis)
    • Scleredema
  • Global Skin Fibrosis Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies 
    • Online Pharmacies 
  • Global Skin Fibrosis Treatment Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Pharmaxis
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Jubilant Cadista
    • Horizon Pharma USA
    • Pfizer
    • Sanofi
    • Hoffmann-La Roche
    • Boehringer Ingelheim
    • Bristol-Myers Squibb Company

 “*” marked represents similar segmentation in other categories in the respective section.

Detailed Segmentation:

  • Global Skin Fibrosis Treatment Market, By Drug Type:
    • Corticosteroids
    • Antifibrotic Drugs
    • Immunotherapy Drugs
    • Other (Immunosuppressant)
  • Global Skin Fibrosis Treatment Market, By Route of Administration:
    • Oral
    • Parenteral
    • Others ( Topical)
  • Global Skin Fibrosis Treatment Market, By Application:
    • Localized forms of scleroderma
    • Eosinophilic fasciitis
    • Scleromyxedema (papular mucinosis)
    • Scleredema
  • Global Skin Fibrosis Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies 
    • Online Pharmacies 
  • Global Skin Fibrosis Treatment Market, By Region:
    • North America
      • By Drug Type
        • Corticosteroids
        • Antifibrotic Drugs
        • Immunotherapy Drugs
        • Other (Immunosuppressant)
      • By Route of Administration
        • Oral
        • Parenteral
        • Others ( Topical)
      • By Application
        • Localized forms of scleroderma
        • Eosinophilic fasciitis
        • Scleromyxedema (papular mucinosis)
        • Scleredema
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies 
        • Online Pharmacies 
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Drug Type
        • Corticosteroids
        • Antifibrotic Drugs
        • Immunotherapy Drugs
        • Other (Immunosuppressant)
      • By Route of Administration
        • Oral
        • Parenteral
        • Others ( Topical)
      • By Application
        • Localized forms of scleroderma
        • Eosinophilic fasciitis
        • Scleromyxedema (papular mucinosis)
        • Scleredema
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies 
        • Online Pharmacies 
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Type
        • Corticosteroids
        • Antifibrotic Drugs
        • Immunotherapy Drugs
        • Other (Immunosuppressant)
      • By Route of Administration
        • Oral
        • Parenteral
        • Others ( Topical)
      • By Application
        • Localized forms of scleroderma
        • Eosinophilic fasciitis
        • Scleromyxedema (papular mucinosis)
        • Scleredema
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies 
        • Online Pharmacies 
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Type
        • Corticosteroids
        • Antifibrotic Drugs
        • Immunotherapy Drugs
        • Other (Immunosuppressant)
      • By Route of Administration
        • Oral
        • Parenteral
        • Others ( Topical)
      • By Application
        • Localized forms of scleroderma
        • Eosinophilic fasciitis
        • Scleromyxedema (papular mucinosis)
        • Scleredema
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies 
        • Online Pharmacies 
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Type
        • Corticosteroids
        • Antifibrotic Drugs
        • Immunotherapy Drugs
        • Other (Immunosuppressant)
      • By Route of Administration
        • Oral
        • Parenteral
        • Others ( Topical)
      • By Application
        • Localized forms of scleroderma
        • Eosinophilic fasciitis
        • Scleromyxedema (papular mucinosis)
        • Scleredema
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies 
        • Online Pharmacies 
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Type
        • Corticosteroids
        • Antifibrotic Drugs
        • Immunotherapy Drugs
        • Other (Immunosuppressant)
      • By Route of Administration
        • Oral
        • Parenteral
        • Others ( Topical)
      • By Application
        • Localized forms of scleroderma
        • Eosinophilic fasciitis
        • Scleromyxedema (papular mucinosis)
        • Scleredema
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies 
        • Online Pharmacies 
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo